Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial.

Autor: Sharma M; Population Health Research Institute, McMaster University, Hamilton, ON, Canada. Electronic address: mike.sharma@phri.ca., Molina CA; Hospital Universitari Vall d'Hebron, Barcelona, Spain., Toyoda K; National Cerebral and Cardiovascular Center, Suita, Osaka, Japan., Bereczki D; Semmelweis University, Budapest, Hungary., Bangdiwala SI; Population Health Research Institute, McMaster University, Hamilton, ON, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Kasner SE; Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA., Lutsep HL; Department of Neurology, Oregon Health & Science University, Portland, OR, USA., Tsivgoulis G; Second Department of Neurology, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece., Ntaios G; Department of Internal Medicine, University of Thessaly, Larissa, Greece., Czlonkowska A; 2nd Department of Neurology, Institute of Psychiatry and Neurology, Warsaw, Poland., Shuaib A; Division of Neurology, Department of Medicine, University of Alberta Hospital, Edmonton, AB, Canada., Amarenco P; Population Health Research Institute, McMaster University, Hamilton, ON, Canada; Department of Neurology and Stroke Center, University of Paris, Bichat Hospital, Paris, France., Endres M; Department of Neurology and Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany., Yoon BW; Uijeongbu Eulji Medical Center, Eulji University, Gyeonggi-do, South Korea., Tanne D; Stroke and Cognition Institute, Rambam Health Care Campus, Haifa, Technion, Israel., Toni D; Emergency Department Stroke Unit, Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy., Yperzeele L; Stroke Unit and Neurovascular Center Antwerp, Department of Neurology, Antwerp University Hospital, Antwerp (Edegem), Belgium., von Weitzel-Mudersbach P; Department of Neurology, Aarhus University Hospital, Aarhus, Denmark., Sampaio Silva G; Universidade Federal de São Paulo/UNIFESP and Hospital Israelita Albert Einstein, São Paulo, Brazil., Avezum A; Centro Internacional de Pesquisa, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Dawson J; School of Cardiovascular and Metabolic Health, College of Medical, Veterinary & Life Sciences, Queen Elizabeth University Hospital, Glasgow, UK., Strbian D; Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland., Tatlisumak T; Department of Clinical Neuroscience/Neurology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg and Department of Neurology, Sahlgrenska University Hospital, Gothenburg, Sweden., Eckstein J; Department of Internal Medicine and Department of Digitalization & ICT, University Hospital Basel, Basel, Switzerland., Ameriso SF; Servicio de Neurología Vascular, Departamento de Neurología, FLENI, Buenos Aires, Argentina., Weber JR; Department of Neurology, Klinikum Klagenfurt, Austria., Sandset EC; Department of Neurology, Oslo University Hospital and The Norwegian Air Ambulance Foundation, Oslo, Norway., Goar Pogosova N; National Medical Research Center of Cardiology after E Chazov, Moscow, Russia., Lavados PM; Departamento de Neurología y Psiquiatría, Unidad de Investigación y Ensayos Clínicos, Clínica Alemana, Universidad del Desarrollo, Santiago, Chile., Arauz A; Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, México City, México., Gailani D; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA., Diener HC; Department of Neuroepidemiology, Institute for Medical Informatics, Biometry and Epidemiology (IMIBE), University Duisburg-Essen, Essen, Germany., Bernstein RA; Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Cordonnier C; University of Lille, Lille, Inserm, CHU Lille, U1172 - LiINCog - Lille Neuroscience & Cognition, F-59000, Lille, France., Kahl A; Bristol Myers Squibb, Princeton, NJ, USA., Abelian G; Bristol Myers Squibb, Princeton, NJ, USA., Donovan M; Bristol Myers Squibb, Princeton, NJ, USA., Pachai C; Bristol Myers Squibb, Princeton, NJ, USA., Li D; Bristol Myers Squibb, Princeton, NJ, USA., Hankey GJ; Medical School, Centre for Neuromuscular and Neurological Disorders, The University of Western Australia, Perth, WA, Australia; Perron Institute for Neurological and Translational Science, Perth, Australia.

Publikováno v: The Lancet. Neurology [Lancet Neurol] 2024 Jan; Vol. 23 (1), pp. 46-59.

Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.

Autor: Conaghan PG; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Leeds, UK. Electronic address: p.conaghan@leeds.ac.uk., Nowak M; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Du S; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Luo Y; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Landis J; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Pachai C; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Fura A; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Catlett IM; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Grasela DM; Research and Early Development, Bristol Myers Squibb, Princeton, NJ, USA., Østergaard M; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Publikováno v: The Lancet. Rheumatology [Lancet Rheumatol] 2023 May; Vol. 5 (5), pp. e263-e273.

Évolution comparative de la voute crânienne et du parenchyme cérébral avec l’âge : étude préliminaire en IRM

Autor: Cotton, F., Euvrard, T., Durand-Dubief, F., Pachai, C., Cucherat, M., Ramirez Rozzi, F., Bonmartin, A., Guihard-Costa, A.M., Tran Minh, V.A., Vallee, B., Froment, J.C.

Publikováno v: In Journal of Neuroradiology 2005 32(2):131-137

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Impact du score d’érosion à l’inclusion sur la réponse thérapeutique et l’évolution radiographique de l’atteinte structurale dans AVERT-2 : un essai randomisé de phase IIIB avec l’abatacept chez des patients atteints de PR récente, naïfs de MTX et ACPA+

Autor: Pachai, C., Connolly, S., Landis, J., Tanaka, Y., Bykerk, V., Huizinga, T., Citera, G., Bingham, C., Wong, R., Huang, K., Du, S., Hayes, W., Wu, C., Fleischmann, R., Gervais, E., Emery, P.

Publikováno v: In Revue du rhumatisme December 2020 87 Supplement 1:A145-A146